Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study

被引：0
|
作者：
Moshe Talpaz
Susan Erickson-Viitanen
Kevin Hou
Solomon Hamburg
Maria R. Baer
机构：
[1] University of Michigan,
[2] Incyte Corporation,undefined
[3] Tower Hematology Oncology Medical Group,undefined
[4] University of Maryland,undefined
[5] Greenebaum Comprehensive Cancer Center,undefined
来源：
Journal of Hematology & Oncology | / 11卷
关键词：
Anemia; Janus kinase; Myelofibrosis; Ruxolitinib; Thrombocytopenia; Transfusion;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study
    Talpaz, Moshe
    Erickson-Viitanen, Susan
    Hou, Kevin
    Hamburg, Solomon
    Baer, Maria R.
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
  • [2] A multinational, open-label, phase 2 study of ruxolitinib in Asian patients with myelofibrosis: Japanese subset analysis
    Oritani, Kenji
    Okamoto, Shinichiro
    Tauchi, Tetsuzo
    Saito, Shigeki
    Ohishi, Kohshi
    Handa, Hiroshi
    Takenaka, Katsuto
    Gopalakrishna, Prashanth
    Amagasaki, Taro
    Ito, Kazuo
    Akashi, Koichi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2015, 101 (03) : 295 - 304
  • [3] A multinational, open-label, phase 2 study of ruxolitinib in Asian patients with myelofibrosis: Japanese subset analysis
    Kenji Oritani
    Shinichiro Okamoto
    Tetsuzo Tauchi
    Shigeki Saito
    Kohshi Ohishi
    Hiroshi Handa
    Katsuto Takenaka
    Prashanth Gopalakrishna
    Taro Amagasaki
    Kazuo Ito
    Koichi Akashi
    International Journal of Hematology, 2015, 101 : 295 - 304
  • [4] Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study
    Ali, Haris
    Tsai, Ni-Chun
    Synold, Timothy
    Mokhtari, Sally
    Tsia, Weimin
    Palmer, Joycelynne
    Stiller, Tracey
    Al Malki, Monzr
    Aldoss, Ibrahim
    Salhotra, Amandeep
    Rahmanuddin, Syed
    Pullarkat, Vinod
    Cai, Ji-Lian
    Stein, Anthony
    Forman, Stephen J.
    Marcucci, Guido
    Mei, Matthew
    Snyder, David S.
    Nakamura, Ryotaro
    BLOOD ADVANCES, 2022, 6 (05) : 1444 - 1453
  • [5] Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis
    Norio Komatsu
    Keita Kirito
    Kazuya Shimoda
    Takayuki Ishikawa
    Kohshi Ohishi
    Kazuma Ohyashiki
    Naoto Takahashi
    Hikaru Okada
    Taro Amagasaki
    Toshio Yonezu
    Koichi Akashi
    International Journal of Hematology, 2017, 105 : 309 - 317
  • [6] Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis
    Komatsu, Norio
    Kirito, Keita
    Shimoda, Kazuya
    Ishikawa, Takayuki
    Ohishi, Kohshi
    Ohyashiki, Kazuma
    Takahashi, Naoto
    Okada, Hikaru
    Amagasaki, Taro
    Yonezu, Toshio
    Akashi, Koichi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2017, 105 (03) : 309 - 317
  • [7] Erratum to: Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis
    Norio Komatsu
    Keita Kirito
    Kazuya Shimoda
    Takayuki Ishikawa
    Kohshi Ohishi
    Kazuma Ohyashiki
    Naoto Takahashi
    Hikaru Okada
    Taro Amagasaki
    Toshio Yonezu
    Koichi Akashi
    International Journal of Hematology, 2017, 105 : 387 - 387
  • [8] Adore: A Randomized, Open-Label, Phase 1/2 Open-Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Patients with Myelofibrosis
    Perkins, Andrew Charles
    Burbury, Kate
    Lehmann, Thomas
    Ross, David M.
    Reiter, Andreas
    Gupta, Vikas
    Harrison, Claire
    Kiladjian, Jean-Jacques
    Vannucchi, Alessandro M.
    Wondergem, Marielle
    Pack, Robert
    Wroclawska, Monika
    Wilke, Celine
    Zhang, Angela
    Heidel, Florian H.
    BLOOD, 2020, 136
  • [9] A Phase 1, open-label, dose-escalation study of selinexor plus ruxolitinib in patients with treatment-naive myelofibrosis
    Ali, Haris
    Kishtagari, Ashwin
    Maher, Keri
    Mohan, Sanjay
    Ansaldo, Karen
    Wang, Xulong
    Chamoun, Kamal
    Prchal, Josef T.
    Tantravahi, Srinivas K.
    CANCER RESEARCH, 2023, 83 (08)
  • [10] A Phase 1, Open-Label, Dose-Escalation Study of Selinexor Plus Ruxolitinib in Patients with Treatment-Naive Myelofibrosis
    Ali, Haris
    Kishtagari, Ashwin
    Maher, Keri
    Mohan, Sanjay R.
    Ansaldo, Karen
    Wang, Xulong
    Chamoun, Kamal
    Prchal, Josef T.
    Tantravahi, Srinivas K.
    BLOOD, 2022, 140 : 3986 - 3987
12345